Efficacy News and Research

RSS

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.

18 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

Research: Urban children spend more time playing outdoors

Young children living in urban public housing spend more time playing outdoors than other urban children, according to researchers at Rice University, Columbia University and Princeton University.

18 Feb 2011

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Cytochroma today announced the initiation of a repeat-dose safety and efficacy study of CTAP101 Capsules in patients with vitamin D insufficiency, secondary hyperparathyroidism (SHPT) and stage 3 chronic kidney disease (CKD).

17 Feb 2011

Iris Pharma announces validation of new EIU model of ocular inflammation

Iris Pharma, a world leader CRO specialized in ophthalmology, today announced the validation of the Endotoxin-Induced Uveitis model, a new model of ocular inflammation.

17 Feb 2011

Inspire fourth quarter revenues increase 2% to $30.3 million

Inspire Pharmaceuticals, announced today financial results for the fourth quarter and year ended December 31, 2010. For the quarter ended December 31, 2010, the Company reported a net loss of $4.3 million, or per common share, compared to a net loss of $2.6 million, or per common share, for the same period in 2009.

17 Feb 2011

Researchers develop new pneumococcal vaccine through novel discovery approach

Pneumococcus accounts for as much as 11 percent of mortality in young children worldwide. While successful vaccines like Prevnar exist, they are expensive and only work against specific pneumococcal strains, with the risk of becoming less effective as new strains emerge.

17 Feb 2011

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Threshold Pharmaceuticals, Inc. today announced that the Company reached agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment for a Phase 3 randomized trial of TH-302 in patients with soft tissue sarcoma.

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas Pharma Inc., a global pharmaceutical company, and AVEO Pharmaceuticals, Inc. today announced that they have entered into a worldwide agreement outside of Asia to develop and commercialize tivozanib, AVEO's lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, for the treatment of a broad range of cancers.

17 Feb 2011

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

Vical Incorporated announced today the issuance of U.S. Patent No. 7,888,112 covering DNA vaccines for cytomegalovirus containing specific gene sequences and formulated with Vical's Vaxfectin adjuvant.

16 Feb 2011

ADVENTRX updates ANX-514 candidate for FDA approval

ADVENTRX Pharmaceuticals, Inc. today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel.

16 Feb 2011

Study: BPS is safe and effective for patients undergoing therapeutic endoscopy

Researchers from Korea report that, compared with conventional sedation, balanced propofol sedation using propofol in combination with midazolam and meperidine, provided higher health care provider satisfaction, better patient cooperation, and similar adverse event profiles in patients undergoing therapeutic endoscopic procedures.

16 Feb 2011

Endosense announces completion of enrollment in EFFICAS I clinical study

Endosense, a Swiss medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the EFFICAS I clinical study.

16 Feb 2011

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Baxter International Inc. announced today results of a study published in this week's issue of The Lancet that demonstrate effectiveness and tolerability of Baxter's PREFLUCEL in protecting against seasonal influenza.

From Baxter International Inc. 15 Feb 2011

Efficacy of zinc in common cold - Review of clinical trials

A new study has added to the existing literature that debates the role of zinc in combating the common cold. It suggests that the supplement might modestly reduce cold duration and severity or maybe even prevent it. The report was published as a Cochrane Review.

15 Feb 2011

Efficacy News and Research

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

TI Pharma launches new research project on stem cell transplant

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Research: Urban children spend more time playing outdoors

Cytochroma initiates CTAP101 repeat-dose safety, efficacy study in vitamin D insufficiency, SHPT and CKD

Iris Pharma announces validation of new EIU model of ocular inflammation

Inspire fourth quarter revenues increase 2% to $30.3 million

Researchers develop new pneumococcal vaccine through novel discovery approach

FDA, Threshold enter agreement on SPA for TH-302 Phase 3 trial in patients with soft tissue sarcoma

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Astellas, AVEO enter development, commercialization agreement for tivozanib

Vical announces issuance of U.S. Patent for cytomegalovirus vaccines

ADVENTRX updates ANX-514 candidate for FDA approval

Study: BPS is safe and effective for patients undergoing therapeutic endoscopy

Endosense announces completion of enrollment in EFFICAS I clinical study

The Lancet publishes Baxter's PREFLUCEL phase III trial results against seasonal influenza

Efficacy of zinc in common cold - Review of clinical trials

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News